Stocks · News reference
Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO Poster
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 8, 2026, 11:13 AM
- Checked
- Jun 8, 2026, 11:20 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics announced that late-breaking data from a proteomic analysis of heart failure biomarkers during lorundrostat treatment will be presented at ENDO 2026. The data comes from post hoc analysis of the Launch-HTN and Advance-HTN trials, which evaluated the aldosterone synthase inhibitor for treating uncontrolled and resistant hypertension.
Read original at globenewswire-inc8-K filing — Mineralys Therapeutics, Inc. (MLYS)
Filed: 2026-06-03 AccNo: 0001628280-26-040225 Size: 543 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar